Evidence map›Paper›PMID 41756403›Full record

ArticleFrontiers in molecular medicine2026

CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse.

Søren Helweg Dam, Giorgia Moranzoni, Magnus Haraldson Høie, Signe Modvig, Karin A W Wadt, Bodil Als-Nielsen, Kjeld Schmiegelow, Kristoffer Vitting-Seerup, Mike Bogetofte Barnkob, Lars Rønn Olsen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Søren Helweg DamLEO foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Giorgia MoranzoniLEO foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Magnus Haraldson HøieDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
Signe ModvigDepartment of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Karin A W WadtDepartment of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
Bodil Als-NielsenDepartment of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
Kjeld SchmiegelowDepartment of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
Kristoffer Vitting-SeerupDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
Mike Bogetofte BarnkobCentre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Department of Clinical Immunology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Lars Rønn OlsenLEO foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapse following anti-CD19 chimeric antigen receptor (CAR) T cell therapy remains a concern in the treatment of refractory B-cell malignancies. Although the CD19

Indexed as

CAR T-cell therapyCD19isoform switchingrelapse predictionsplice variant

Identifiers

PMID41756403
PMCPMC12935319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.